Showing 6,008 results

Filters Content type: News, Editors' picks, About HIV Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Adherence

Substance use does not lower adherence to PrEP in MSM

Editor's pick
Healio
24 November 2018
Bad science & bogus treatments

GcMAF: Unlicensed HIV drug 'nearly killed patient'

Editor's pick
BBC News
23 November 2018
Cardiovascular disease

What triggered my heart attack?

Editor's pick
EATG
19 November 2018
New & experimental HIV treatments

Tivicay Plus Boosted Prezista Shows Promise as Two-Drug HIV Regimen

Editor's pick
Poz
16 November 2018
Treatment interruptions

Community Recommendations for Clinical Research Involving Antiretroviral Treatment Interruptions in Adults

Editor's pick
TAG
15 November 2018
Injectable & long-acting PrEP

Removable PrEP implant produces high drug levels in rabbits; further studies planned

News
15 November 2018
Undetectable viral load & treatment as prevention

Viral load in semen rapidly rebounds to infectious levels during HIV treatment breaks

News
14 November 2018
Bad science & bogus treatments

Fake news, real consequences: What happens after headlines about false HIV 'cures'

Editor's pick
Bhekisisa
9 November 2018
Transgender people

Transgender women taking PrEP have lower levels of PrEP drugs, especially in rectal tissues, than cisgender men

News
9 November 2018
Experiences of stigma

Linking HIV stigma, denial and poor health 

Editor's pick
AVERT
8 November 2018
Starting treatment

Early HIV treatment reduces the risk of liver fibrosis

News
8 November 2018
New & experimental HIV treatments

Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left

News
7 November 2018
Bad science & bogus treatments

Gammora does not cure HIV

News
6 November 2018
Treatment simplification strategies

Dolutegravir plus darunavir maintains viral suppression without NRTIs

News
6 November 2018
Injectable & long-acting HIV treatment

ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

Editor's pick
Poz
5 November 2018
Heterosexual men

Reaching the men: who are the partners of the young women with HIV in South Africa?

News
5 November 2018
People with limited treatment options

Prolonged HIV suppression is possible using ibalizumab, analysis of highly drug-resistant people shows

News
2 November 2018
PrEP science

How safe is PrEP? Meta-analysis finds no increased risk of serious side-effects

News
2 November 2018
Undetectable viral load & treatment as prevention

aidsmapLIVE: AIDS 2018 special Video

November 2018
Cardiovascular disease

Cardiovascular Risk Unclear for HIV Patients on Dolutegravir

Editor's pick
Medscape (requires free registration)
1 November 2018
Starting treatment

Janssen Presents Positive Long-Term Efficacy and Safety of SYMTUZA in Treatment-Naïve Adults with HIV-1

Editor's pick
Janssen press release
1 November 2018
Starting treatment

Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Editor's pick
Gilead press release
1 November 2018
Starting treatment

Dolutegravir or lower-dose efavirenz equally effective, but less resistance with dolutegravir

News
1 November 2018
Bad science & bogus treatments

'No cure' for HIV in Zimbabwe says UN, following claims from local preacher

Editor's pick
UN News
1 November 2018